ClinicalTrials.gg
RecruitingNCT07862647CV01-104Updated Oct 9, 2026

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

A Phase 1 interventional study of 5-ALA and Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound in Glioblastom WHO Grade 4, GBM and bGBM, sponsored by Alpheus Medical, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Alpheus Medical, Inc. · Phase 1, Interventional, and Treatment

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing Aminolevulinic Acid in Glioblastoma — 2 open to participants now, 3 under way, none of them phase 3. Aminolevulinic Acid · Glioblastoma.

Planned enrollment
8th of 20
30 · median 17
Started
2026
the only one that year
Phase 1
4 of 20
1 open now
Registered
20th of 20
by date
Lead sponsor
2 of 20
Alpheus Medical, Inc.

Among the 20 studies testing Aminolevulinic Acid in Glioblastoma, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1, and was the 20th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

2 of the 20 studies testing Aminolevulinic Acid in Glioblastoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Aminolevulinic Acid in Glioblastoma, or all of them as a file.
02

Study summary

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

03

Conditions studied

  • Glioblastom WHO Grade 4
  • GBM
  • bGBM
  • Butterfly GBM
  • Bihemispheric GBM
  • Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient, or the patient's legally authorized representative, must provide , stating understanding of the procedures and nature of the study treatment, and willingness to comply with study requirements
  2. ≥ 18 and ≤ 80 years of age
  3. of ≤ 2 at screening
  4. Newly diagnosed proven glioblastoma (WHO criteria 2021), with absence of IDH mutation demonstrated by negative IDH1 R132H staining on immunohistochemistry or equivalent molecular testing.
  5. Patients must have a radiographic butterfly glioma phenotype on MRI, defined as a contiguous enhancing glioma involving both cerebral hemispheres with midline extension through the corpus callosum (genu, body, and/or splenium) or other commissural pathway. Patients must not have started TMZ/RT. Bilateral involvement must reflect continuous tumor spread across the midline and not merely bilateral edema, mass effect, multifocal non-contiguous disease, or separate bilateral lesions. Note:

    patients must have undergone prior or decompressive surgery with histopathologic confirmation of butterfly glioma.

  6. Adequate bone marrow and organ function, defined by the following laboratory values:

    1. (ANC) ≥ 1000 cells/mm3
    2. count ≥ 50,000 cells/mm3
    3. (Hgb) ≥ 8 g/dL
    4. (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (ULN)
    5. Total ≤ 1.5 x ULN (unless gilbert's syndrome, then patients may be eligible if total serum bilirubin is ≤ 3.0 x ULN or direct bilirubin is ≤ 1.5 x ULN)
    6. (CrCl) as estimated by Cockcroft-Gault equation of ≥ 50 mL/min
  7. Adequate coagulation function defined as PT ()/PTT (partial thromboplastin time) defined as either results within normal institutional values or not considered \<1.5 x ULN.
  8. Non-pregnant, non-lactating females who are , surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation or hysterectomy), or who agree to use effective methods as defined by the protocol during the study and for 30 days after the last investigational treatment, see Appendix 1. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea and a serum follicle stimulating hormone (FSH) concentration ≥ 40 IU/L, or at least 6 weeks following surgical menopause (bilateral oophorectomy). See Appendix 1, females on HRT and whose menopausal status is in doubt will be required to use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
  9. Women of must have a negative serum human chorionic gonadotropin (hCG) pregnancy test within 7 days prior to first 5-ALA administration
  10. Male patients must be surgically sterile (i.e., > 3 months post-vasectomy) or willing to use a highly effective double-barrier contraception method (e.g., male condom with diaphragm or male condom with cervical cap) for the duration of the study and for at least 30 days following SDT treatment. Male patients must not donate sperm from the time of study drug dosing until 30 days following SDT treatment.

Exclusion criteria

Exclusion Criteria:

  1. Any component of the tumor in the infratentorial location (cerebellar or brainstem tumors are excluded)
  2. Commencing TMZ + RT per SOC before the first SDT treatment
  3. use > 4 mg/day of dexamethasone (or equivalent), steroid dose should be stable or decreasing for ≥1 week prior to randomization
  4. Inability to undergo MRI or receive gadolinium (Gd)-based contrast agents
  5. to 5-ALA or porphyrins
  6. Patient head size > 16.6 cm in breadth (max width of head, above the ears) and > 21.3 cm in length (front to back) to ensure fit within the helmet transducer array.
  7. Skull voids/defects > 10 mm diameter if defect is open, or > 14 mm if defect is covered with titanium burr hole cover, titanium mesh, or similar repair hardware. Note, Longeviti Neuro Solutions or other sonolucent implants should be treated as open defects and therefore may not exceed 10 mm in diameter.
  8. Hemorrhagic or ischemic stroke (including ) and central nervous system bleeding in the preceding 6 months that are not related to glioma surgery. History of prior intratumoral bleeding prior to screening is not an exclusion criterion; however, patients with a history of prior intratumoral or intracranial bleeding will undergo a non contrast head CT to exclude acute bleeding.
  9. Has any history of glioma, a concurrent , or malignancy within 3 years of randomization, unless definitive therapy is completed, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy
  10. Patients who have cerebral edema requiring urgent intervention (e.g., surgery, unstable or escalating high doses of steroids).
  11. Patients with rapid clinical deterioration that, in the opinion of the investigator, is likely to worsen during the first cycle of treatment.
  12. Acute or chronic types of porphyria.
  13. Gastrointestinal disorder that negatively affects absorption.
  14. Known active or C (Note: testing is not required).
  15. Known (HIV) infection (Note: testing is not required).
  16. Participation in another interventional clinical trial for butterfly glioma/GBM. (Observational studies are allowable)
  17. Unable to avoid phototoxic drugs (e.g., St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, quinolones, and tetracyclines) for 24 hours prior to and following 5-ALA administration.
  18. Any other concurrent severe or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, cardiac disease, clinically significant psychiatric or neurological disorder, active or uncontrolled infection).
  19. Women who are pregnant or breastfeeding
  20. Patients with a condition the Investigator believes would interfere with the ability to comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    5-ALA + LIDU SDT System for newly diagnosed butterfly glioma

    Patients with newly diagnosed bihemispheric GBM will receive up to 2 treatments of 5-ALA + PoMA with the LIDU ultrasound device prior to receiving standard chemotherapy radiation treatment. Patients will then complete 6 weeks of SOC chemoradition (CRT). After completion of CRT, patients will receive 4 more treatments, 1 treatment every 28 days, of 5-ALA + PoMA.

    Drug: 5-ALA · Device: Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound

Interventions

  • Drug5-ALA

    5-ALA is an oral drug that is taken prior to PoMA

  • DevicePorphyrin Metabolite Activation (PoMA) with LIDU ultrasound

    Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    To assess the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 in patients receiving bi-hemispheric 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound.

    Time frame: up to 30 weeks

Secondary outcomes

  1. To assess overall response rate

    Overall Response Rate (ORR), defined as the percentage of participants achieving a complete response or partial response according to RANO 2.0 criteria.

    Time frame: 1 year

  2. Duration of Response

    The length of time a patient experiences stability, or shrinkage of tumor

    Time frame: 1 year

  3. median PFS

    The time from first treatment until disease progression or death from any cause. The median is the time by which 50% of patients have experienced progression

    Time frame: 1 year

  4. Median Overall Survival

    The time from the first treatment until death from any cause. The median is the time by which 50% of patients have died and 50% remain alive.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 7, 2026
StartEst.
Oct 29, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTo assess overall response rate: how it is measured was reworded
Oct 9, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 9, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTo assess overall response rate: how it is measured was reworded
    + 1 other change: verification date
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862647
Lead sponsor
Alpheus Medical, Inc.
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 29, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Ann-Marie Hulstine
Contact
AMHulstine@alpheusmedical.com
484-252-1960

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion